Unlocking the power of PBPK prediction and ADMET experimentation for a better drug development
In the ever-evolving landscape of pharmaceutical research, the quest for developing safer and more effective drugs is a continuous endeavor. Two crucial pillars in this journey are PBPK (physiologically-based pharmacokinetic) modeling and ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) experimentation. Alone, each of these approaches plays a significant role in drug development, but their true potential is realized when they work hand in hand. PhinC Development (PhinC) and Oncodesign Services (ODS) are joining forces in order to provide valuable data. We’ve asked our experts what this partnership means to them.
Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services. It contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vivo/in vitro pharmacology. Oncodesign Services has 230 employees in France and Canada.
PhinC Development is the expert partner for small to medium sized pharmaceutical or biotech companies, who need to move forward in early drug research. Thanks to a multidisciplinary team with thorough field experience, PhinC Development helps to take the best decisions concerning drug development using all existing pharmacology and pharmacometrics modeling & simulation (M&S) tools.